HOME >> BIOLOGY >> NEWS
ChemGenex uses genomics approach to develop new anticancer drug, predict possible side effects

Gene expression changes in response to drugs in cell culture and living systems provide unique insights for their development and use

MENLO PARK, CA (October 30, 2001): Most genomics research is currently aimed at identifying and validating new gene targets for use in early stage drug discovery. However, genomics can also play a key role now in preclinical and clinical drug development, including predicting potential drug toxicities and helping developers design clinical trials, say scientists from ChemGenex Therapeutics. They discussed data today illustrating the use of chemical genomics approaches in evaluating the potential of their investigational drug called Ceflatonin against leukemias and human solid tumors. The researchers presented their findings at the American Association of Cancer Research National Cancer Institute European Organization for Research and Treatment of Cancer conference on Molecular Targets and Cancer Therapeutics taking place from October 29 to November 3 in Orlando, Florida.

Understanding how genes perform in response to chemicals in cell cultures, as well as in diseased and normal tissues in living systems can help researchers identify and evaluate potential new drugs more efficiently than ever before, said Dennis Brown, Ph.D., chairman, chief executive officer and founder of ChemGenex Therapeutics, Inc.

Such knowledge can help spotlight possible drug toxicities, as well as identify which patients may best benefit from treatment with a specific drug, he continued. In addition, chemical genomics can aid in the design of efficient clinical trials by helping trial designers predict the most effective doses and dose scheduling, as well as provide key insights into drug bioavailability, distribution and metabolism. Using genomics in this way to help patients receive most effectively those medicines that will be most useful to them is a major goal of the genomics revolution.

Based on its chem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
30-Oct-2001


Page: 1 2 3

Related biology news :

1. International symposium on nutritional genomics
2. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics
3. Full promise of genomics in disease research yet to be realized
4. Pharmacogenomics could replace trial-and-error with science from the human genome
5. Dartmouth Medical School awarded $9 million grant for genomics research
6. Functional genomics enables easy target identification and drives drug discovery
7. Library on a Slide: Whole genome microarrays for comparative genomics
8. New genomics tool boosts diabetes research
9. Bacteriophage genomics approach to antimicrobial drug discovery published in Nature Biotechnology
10. Emerging frontiers genomics grant for blue-green bacteria
11. What can the genomics revolution teach us about global change?

Post Your Comments:
(Date:10/31/2014)... the war against Ebola one important hurdle has just ... at the University of North Carolina at Chapel Hill ... mice that can be infected with Ebola and display ... published in the current issue of Science , ... vaccines, which are desperately needed to curb the worldwide ...
(Date:10/31/2014)... Adelaide-led project has developed a new test that can ... H5N1 strain of avian influenza virus or "bird flu" ... is a significant step in the fight against this ... in the poultry populations of South East Asia, particularly ... of its possible transmission to humans and the threat ...
(Date:10/31/2014)... 2014  HITLAB SM , a healthcare innovation ... inaugural HITLAB Innovators Summit SM on December ... will partner with the Clinton Foundation,s Health Matters ... Columbia Business School Alumni Club of ... and Operations Research, bringing together leaders in healthcare ...
Breaking Biology News(10 mins):Improved mouse model will accelerate research on potential Ebola vaccines, treatments 2New step towards eradication of H5N1 bird flu 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3
(Date:10/30/2014)... 30, 2014 Spartan Bioscience announced today ... CYP2C19 System . It detects CYP2C19 genetic mutations in ... , The Spartan RX CYP2C19 System is the first ... approved in Canada. Due to the system’s ease of ... used by healthcare professionals such as doctors, nurses, pharmacists, ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... will present a company overview at the Nomura Biotechnology Conference ... Boston, MA. A live ... & Media" section of the Company,s website, www.isispharm.com .  ... 48 hours and will be archived for a limited time. ...
(Date:10/30/2014)...  Regado Biosciences, Inc. (Nasdaq: RGDO ), ... and live audio webcast on Thursday, November 6, 2014, ... 2014 financial results. Interested participants and investors ... for domestic callers or (412) 902-4276 for international callers. ... investor relations section of the Regado website at ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
Cached News: